SGLT2i (Foxiga, Jadiance), increased urine output (adverse reactions)

SGLT2i를 다뇨 때문에 복용하지 못하는 환자가 있습니다. 포시가와 자디앙에서 3% 정도 보고됩니다.

​

Foxiga

1% to 10%:

Endocrine & metabolic: Dyslipidemia (3%), hypovolemia (1% to 3%)

Gastrointestinal: Nausea (3%)

Genitourinary: Dysuria (2%), increased urine output (3% to 4%), urinary tract infection (6%; including pyelonephritis and urinary tract infection with sepsis)

Hematologic & oncologic: Increased hematocrit (1%)

Infection: Genitourinary fungal infection (3% to 8%, including vulvovaginal candidiasis [females] and balanitis [males]), influenza (3%)

Neuromuscular & skeletal: Back pain (4%), limb pain (2%)

Respiratory: Nasopharyngitis (7%)

​

<1%:

Dermatologic: Severe dermatological reaction

Endocrine & metabolic: Ketoacidosis (including diabetic ketoacidosis and euglycemia ketoacidosis [Leader 2019])

Hypersensitivity: Anaphylaxis (severe), angioedema

​

​

Jadiance

1% to 10%:

Endocrine & metabolic: Dyslipidemia (4%), increased thirst (2%)

Gastrointestinal: Nausea (2%)

Genitourinary: Genitourinary fungal infection (2% to 6%), increased urine output (3%), urinary tract infection (8% to 9%; incidence higher in females)

Hematologic & oncologic: Increased hematocrit (3% to 4%)

​

REF. UpToDate 2022.06.21